[{"id":"eaf46f3b-62ac-4be1-99ad-a5ae1add35c7","acronym":"TQB2102-III-01","url":"https://clinicaltrials.gov/study/NCT06561607","created_at":"2025-02-26T09:49:56.775Z","updated_at":"2025-02-26T09:49:56.775Z","phase":"Phase 3","brief_title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","source_id_and_acronym":"NCT06561607 - TQB2102-III-01","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • albumin-bound paclitaxel • TQB2102"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 542","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-08-20"},{"id":"6c155d5d-8320-4211-8cb5-b8b70816afda","acronym":"","url":"https://clinicaltrials.gov/study/NCT06115902","created_at":"2023-11-03T21:12:42.459Z","updated_at":"2024-07-02T16:35:27.721Z","phase":"Phase 1","brief_title":"A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer","source_id_and_acronym":"NCT06115902","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQB2102"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/17/2023","start_date":" 11/17/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-11-29"},{"id":"a26b0962-bd0b-4231-9b68-3850cd606607","acronym":"","url":"https://clinicaltrials.gov/study/NCT05735496","created_at":"2023-02-21T16:01:48.914Z","updated_at":"2024-07-02T16:35:54.684Z","phase":"Phase 1","brief_title":"Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers","source_id_and_acronym":"NCT05735496","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQB2102"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-02-27"}]